Tyrosine kinase receptor
From Proteopedia
(Difference between revisions)
| Line 45: | Line 45: | ||
**[[4asz]] – hTRK-B kinase domain<BR /> | **[[4asz]] – hTRK-B kinase domain<BR /> | ||
**[[4at3]], [[4at4]], [[4at5]] – hTRK-B kinase domain + inhibitor<BR /> | **[[4at3]], [[4at4]], [[4at5]] – hTRK-B kinase domain + inhibitor<BR /> | ||
| - | **[[ | + | **[[4mfq]] – hTRK-B kinase domain + FRS2A - NMR<BR /> |
*TRK-C or NT-3 growth factor receptor | *TRK-C or NT-3 growth factor receptor | ||
| Line 52: | Line 52: | ||
**[[4pbv]], [[4pbw]] – hTRK-C extracellular domain (mutant) + tyrosine phosphatase s<BR /> | **[[4pbv]], [[4pbw]] – hTRK-C extracellular domain (mutant) + tyrosine phosphatase s<BR /> | ||
**[[3v5q]], [[4ymj]], [[6kzc]], [[6kzd]] – hTRK-C kinase domain + inhibitor<BR /> | **[[3v5q]], [[4ymj]], [[6kzc]], [[6kzd]] – hTRK-C kinase domain + inhibitor<BR /> | ||
| + | |||
| + | *TrkA potassium uptake protein | ||
| + | |||
| + | **[[4j9v]] – VpTrkA + ATP – ''Vibrio parahaemolyticus''<br /> | ||
| + | **[[6v4j]], [[6v4l]] – VpTrkA + TrkH + ATP <br /> | ||
| + | **[[6v4k]] – VpTrkA + TrkH + ADP<br /> | ||
| + | **[[4j9u]] – VpTrkA + TrkH + NAD<br /> | ||
| + | |||
| + | *TrkH potassium uptake protein | ||
| + | |||
| + | **[[3pjz]] – VpTrkH<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 08:46, 14 June 2022
| |||||||||||
3D Structures tyrosine kinase receptor
Updated on 14-June-2022
References
- ↑ Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. PMID:29455648 doi:http://dx.doi.org/10.1186/s12943-018-0782-4
- ↑ Deinhardt K, Chao MV. Trk receptors. Handb Exp Pharmacol. 2014;220:103-19. doi: 10.1007/978-3-642-45106-5_5. PMID:24668471 doi:http://dx.doi.org/10.1007/978-3-642-45106-5_5
- ↑ Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014, Jan 3. PMID:24390213 doi:http://dx.doi.org/10.1038/modpathol.2013.233
- ↑ Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050., eCollection 2015 May 14. PMID:26005534 doi:http://dx.doi.org/10.1021/acsmedchemlett.5b00050
- ↑ Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034
